Novartis to acquire Excellergy for up to $2 billion
Acquisition to advance potentially first-in-class trifunctional effector cell response inhibitors for severe allergies
Excellergy to be acquired by Novartis for up to $2 billion
Acquisition to advance potentially first-in-class trifunctional effector cell response inhibitors
DFI Retail Partners with SymphonyAI to Drive AI-Driven Merchandising Capabilities
Leading Asian retailer aims to strengthen its merchandise planning foundation with unified, data-driven retail intelligence